TORONTO, Feb. 19 /CNW/ - A new analysis from the JUPITER study presented
today at the International Stroke Conference (ISC) in San Diego, California,
describes details of the stroke data according to gender, ethnicity and
baseline risk factors. This data adds to the primary analysis of the JUPITER
study which demonstrated that CRESTOR(R) (rosuvastatin calcium) 20mg
significantly reduced the risk of stroke by nearly half (48%; p=0.002),
compared to placebo among men and women with elevated high sensitivity
C-reactive protein (hsCRP) but low to normal cholesterol levels.(1)
"Today's analysis of the JUPITER data clearly indicated that people who
were smokers, over 70 years of age, had high blood pressure, or were at
greater overall risk for cardiovascular disease, as well as those with
elevated hsCRP levels, received notable benefit from treatment with
rosuvastatin 20mg," said Dr. Jacques Genest, Director, Cardiology Division,
McGill University Health Centre.
There was no increase in the risk of hemorrhagic stroke (p=0.44 vs
placebo) in patients treated with rosuvastatin. Rosuvastatin 20mg was well
tolerated in nearly 9,000 patients during the course of the JUPITER study.
"Cardiovascular disease is one of the leading causes of death in
Canada,(2)" said Dr. Jefferson Tea, Medical Advisor, Cardiovascular,
AstraZeneca Canada Inc. "This additional analysis of the JUPITER study
underscores AstraZeneca's commitment to conducting research that will improve
the lives of patients."
Initial results from JUPITER, originally presented in November 2008 at
the American Heart Association's Annual Scientific Sessions and published by
the New England Journal of Medicine, showed rosuvastatin 20mg significantly
reduced major cardiovascular (CV) events (combined risk of myocardial
infarction, stroke, arterial revascularization, hospitalization for unstable
angina, or death from CV causes) by 44% compared to placebo (p(less
than)0.00001).(1) These results also showed that for patients in the trial
taking rosuvastatin 20mg the combined risk of heart attack, stroke or CV death
was reduced by nearly half (47%, p(less than)0.00001).(1)
CRESTOR is indicated as an adjunct to diet in the treatment of high
cholesterol. CRESTOR is not indicated for the prevention of cardiovascular
events including stroke. CRESTOR should be used according to the prescribing
information, which contains recommendations for initiating and titrating
therapy according to the individual patient profile. In Canada, the
recommended starting dose of CRESTOR in most patients is 10mg orally once
With over 160 million prescriptions written worldwide, CRESTOR has been
prescribed to more than 15 million patients and has a safety profile in line
with that of other marketed statins.
JUPITER (Justification for the Use of statins in Primary prevention: an
Intervention Trial Evaluating Rosuvastatin) was a long-term, randomized,
double-blind, placebo-controlled, large-scale study of 17,802 patients
designed to determine if rosuvastatin 20 mg decreases the risk of heart
attack, stroke and other major cardiovascular events in patients with low to
normal LDL-C but at increased cardiovascular risk as identified by elevated
high-sensitivity C-reactive protein (hsCRP) and age. The majority of patients
had at least one other risk factor including hypertension, low HDL-C, family
history of premature coronary heart disease (CHD) or smoking. hsCRP is a
recognized marker of inflammation which is associated with an increased risk
of atherosclerotic cardiovascular events.
JUPITER is a part of AstraZeneca's extensive GALAXY clinical trials
programme, designed to address important unanswered questions in statin
research. Currently, more than 69,000 patients have been recruited from 55
countries worldwide to participate in the GALAXY Programme.
AstraZeneca is a major international healthcare business engaged in the
research, development, manufacturing and marketing of meaningful prescription
medicines and supplier for healthcare services. AstraZeneca is one of the
world's leading pharmaceutical companies with healthcare sales of US$ 31.6
billion and is a leader in gastrointestinal, cardiovascular, neuroscience,
respiratory, oncology and infectious disease medicines. For more information
about AstraZeneca, please visit: www.astrazeneca.ca.
(1) Ridker, PM, Danielson, E, Fonseca, FAH, Genest, J, Gotto, A,
Kastelein, JJP, Koenig, W, Libby, P, Lorenzatti, AJ, MacFadyen, JG,
Nordestgaard, BG, Shepherd, J., Willerson, JT, Glynn, RJ. Rosuvastatin to
Prevent Vascular Events in Men and Women with Elevated C-Reactive
Protein. N Engl J Med 2008; 359, 2195-207.
(2) Statistics Canada. The Daily, Thursday, December 4, 2008. Available
Accessed on February 18, 2009.
For further information:
For further information: Alexis Mantell, Fleishman-Hillard Canada Inc.,
(416) 598-5774 office, (416) 275-6698 mobile, firstname.lastname@example.org;
Lauren Joakim, Fleishman-Hillard Canada Inc., (416) 598-5799 office, (647)
504-5162 mobile, email@example.com